profit from every $100 of sales.
$0$100
Henry Schein
$86.22+0.09% today
+17.6% in 1 year
1-year low $68.991-year high $90.86
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $23.95 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Henry Schein sold, what it kept, and what it did with the cash.
Sales went from $12.6 billion in 2022 to $13.2 billion in 2025, with $398 million of profit last year.
SalesProfit
Henry Schein handed back more cash to shareholders than it generated last year.
Buybacks $850M
Free cash flow 2025$521M
Bought back its own shares$850M
Paid as dividends–
Cash vs. debt$156M vs. $3.4B
Henry Schein vs. similar companies
Henry Schein grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Henry Schein | 23.9× · Fair price | ||
 McKesson | 26.7× · Fair price | ||
 Cencora | 44.1× · Expensive | ||
 Cardinal Health | 41.6× · Expensive | ||
 Sigma Healthcare | 63.0× · Very expensive |
AI analysis
An AI analyst reads Henry Schein's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 10,119 | 12,401 | 12,647 | 12,339 | 12,673 | 13,184 | |
| 2,816 | 3,674 | 3,831 | 3,860 | 4,016 | 4,105 | |
| – | – | 878 | 695 | 731 | 758 | |
| 711 | 1,053 | 950 | 851 | 912 | 964 | |
| 404 | 631 | 538 | 416 | 390 | 398 | |
| 2.82 | 4.45 | 3.91 | 3.16 | 3.05 | 3.27 | |
| 27.8% | 29.6% | 30.3% | 31.3% | 31.7% | 31.1% | |
| – | – | 6.9% | 5.6% | 5.8% | 5.7% | |
| 4.0% | 5.1% | 4.3% | 3.4% | 3.1% | 3.0% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 7,773 | 8,481 | 8,607 | 10,573 | 10,218 | 11,215 |
| Cash | 421 | 118 | 117 | 171 | 122 | 156 |
| Total debt | – | 1,217 | 1,497 | 2,741 | 2,870 | 3,436 |
| Total liabilities | 3,460 | 3,805 | 3,936 | 5,420 | 5,381 | 6,421 |
| 3,348 | 3,425 | 3,446 | 3,655 | 3,393 | 3,245 | |
| 143 | 142 | 138 | 132 | 128 | 122 | |
| 12.8% | 14.6% | 12.1% | 7.8% | 8.1% | 8.1% | |
| 12.1% | 18.4% | 15.6% | 11.4% | 11.5% | 12.3% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 599 | 710 | 602 | 500 | 848 | 712 | |
| – | – | 128 | 187 | 187 | 191 | |
| – | – | 474 | 313 | 661 | 521 | |
| Dividends paid | – | – | – | – | – | – |
| 74 | 401 | 485 | 250 | 385 | 850 | |
| 9 | 78 | 54 | 39 | 39 | 39 |
Valuation
- 23.9×
- 16.2×
- 7.97
- 3.0×
- 0.7×
- 18.3×
- 13.3×
- 5.5%
- 4.2%
- 0.0%
Profitability
- 31.1%
- 5.7%
- 3.0%
- 7.4%
- 8.3%
- 9.2%
- 11.9%
- 3.5%
- 9.4%
- –
Growth
- +5.4%
- +3.0%
- −13.3%
- –
- −4.0%
Financial health
- 3.4×
- 1.06
- 33.2%
- 4.6×
- 1.38
- 0.75
- 1.18
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 36%of 946
Bottom 42%of 872
Top 40%of 563
Bottom 29%of 868
Top 18%of 986
What analysts expect
- Average price target
- $86.43
- Range
- $64.00 – $100.00
- 4 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | 1.32 | 1.20 | +10.0% |
| Feb 24, 2026 | 1.34 | 1.30 | +3.1% |
| Nov 4, 2025 | 1.38 | 1.27 | +8.7% |
| Aug 5, 2025 | 1.10 | 1.18 | −6.8% |
| May 5, 2025 | 1.15 | 1.11 | +3.6% |
| Feb 25, 2025 | 1.19 | 1.23 | −3.3% |
| Nov 5, 2024 | 1.22 | 1.16 | +5.2% |
| Aug 6, 2024 | 1.23 | 1.22 | +0.8% |
News
Jack Henry discloses cyber incident, says operations unaffectedSeeking Alpha · Aug 31, 2026The newest story we have is from Aug 31, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
47No pass
Benjamin Graham
44No pass
Philip Fisher
39No pass
Peter Lynch
16No pass
Joel Greenblatt
26No pass
Charlie Munger
30No pass
Terry Smith
33No pass
Questions about Henry Schein
Is Henry Schein a good stock to buy?
A business with weak numbers at a fair price. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Henry Schein AI analysis
What does Henry Schein do?
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. It is in Medical Distribution, based in Melville, NY, United States, with 25,000 employees.
Does Henry Schein pay a dividend?
No. Henry Schein does not pay a dividend at the moment; in 2025 it returned $850 million to shareholders by buying back its own shares.
Is Henry Schein stock halal?
No. Henry Schein does not pass our halal screen: its debt is 36% of its market value, at or above the 33% limit. How we check
How has Henry Schein stock done over the past year?
Up 17.6% over the past twelve months, to $86.22. It traded between $68.99 and $90.86 and is 5.1% below its high.
Who are Henry Schein's competitors?
The largest listed companies in the same industry are McKesson, Cencora, Cardinal Health and Sigma Healthcare. The peers table on this page compares their profit, growth and price with Henry Schein's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.